Images

Filter by

Table 4 ESC 2016 Guidelines on Atrial Fibrillation. Recommendations for Secondary Stroke Prevention
Table 4: ESC 2016 Guidelines on Atrial Fibrillation. Recommendations for Secondary Stroke Prevention
Figure 1 Initiation or Continuation of Anticoagulation in Atrial Fibrillation Patients After a Stroke or Transient Ischaemic Attack
Figure 1: Initiation or Continuation of Anticoagulation in Atrial Fibrillation Patients After a Stroke or Transient Ischaemic Attack
Figure 2 Initiation or Resumption of Anticoagulation in Atrial Fibrillation Patients After an Intracranial Bleed
Figure 2: Initiation or Resumption of Anticoagulation in Atrial Fibrillation Patients After an Intracranial Bleed
Table 5 ESC 2016 Guidelines on Atrial Fibrillation. Recommendations for Management of Bleeding
Table 5: ESC 2016 Guidelines on Atrial Fibrillation. Recommendations for Management of Bleeding
Figure 3 Management of Active Bleeding in Patients Receiving Anticoagulation
Figure 3: Management of Active Bleeding in Patients Receiving Anticoagulation
Figure 4 Whether to Interrupt and How to Interrupt for Vitamin K Antagonists
Figure 4: Whether to Interrupt and How to Interrupt for Vitamin K Antagonists
Figure 5 Whether to Bridge and How to Bridge for Direct Oral Anticoagulants and Vitamin K Antagonists
Figure 5: Whether to Bridge and How to Bridge for Direct Oral Anticoagulants and Vitamin K Antagonists
Table 6 AHA/ACC 2017 Update of the 2014 Guidelines on Valve Disease. Bridging Therapy for Prosthetic Heart Valves
Table 6: AHA/ACC 2017 Update of the 2014 Guidelines on Valve Disease. Bridging Therapy for Prosthetic Heart Valves
Table 7 EHRA 2015 Last Intake of Non-vitamin K Antagonist Oral Anticoagulant Before Elective Surgical Intervention
Table 7: EHRA 2015: Last Intake of Non-vitamin K Antagonist Oral Anticoagulant Before Elective Surgical Intervention
ACC 2017 Recommended Durations for Withholding Direct Oral Anticoagulants Based on Procedural Bleed Risk and Estimated CrCI When There Are No Increased Patient Bleed Risk Factors
ACC 2017: Recommended Durations for Withholding Direct Oral Anticoagulants Based on Procedural Bleed Risk and Estimated CrCI When There Are No Increased Patient Bleed Risk Factors
Figure 6 Whether to Interrupt and How to Interrupt for Direct Oral Anticoagulants
Figure 6: Whether to Interrupt, and How to Interrupt for Direct Oral Anticoagulants
Figure 1 Dual Pathway Electrophysiology of AVN
Figure 1: Dual Pathway Electrophysiology of AVN